Amaryl
AssetAlso called HOE 490, NSC-759809, Glimepiride, Niddaryl
- Stage
- Approved, not sold in the US
- Modality
- Small molecule
- Target
- ABCC8
- 3
- Indications
- 69
- Trials
- 1
- Developer
Approved by the FDA on Nov 30, 1995 (NDA020496). Not sold in the US: Drugs@FDA marks every US product that holds it discontinued. FDA
Indications
3No named disease
Approved, not sold in the US, FDA, Nov 30, 1995
Type 2 diabetes
Phase 3, Completed, NCT00044447, clinicaltrials.gov, Oct 31, 2026
Diabetes mellitus
Phase 3, Completed, NCT00642915, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism3
- Owner and partners1
- Trials69
- Evidence for its targets3
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.